Navigation Links
Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
Date:8/23/2010

rially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, SGX201, RiVax™, and LPM™, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: the FDA's requirement that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec® will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; Soligenix is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec® may not gain market acceptance if it is eventually approved by the FDA;
'/>"/>
SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 12, 2014 Research and Markets ( ... "Inferior Vena Cava (IVC) Filters - Global Trends, Estimates ... http://photos.prnewswire.com/prnh/20130307/600769 Global ... reach US$435 million by 2016. The North ... the global value while Europe ...
(Date:12/15/2014)... , December 15, 2014 BerGenBio ... for aggressive drug resistant cancers, today announces that it ... private placing from new and existing investors. ... support the development of its pipeline of innovative cancer ... its lead drug candidate, BGB324, a first-in-class selective Axl ...
(Date:12/15/2014)... PLYMOUTH MEETING, Pa. , Dec. 15, 2014 ... ) announced today it has been added to ... the NASDAQ Biotechnology Index will become effective upon ... The NASDAQ Biotechnology Index is designed to track ... that are classified as either biotechnology or pharmaceutical ...
Breaking Medicine Technology:Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4BerGenBio Completes NOK90 Million Fundraising 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
(Date:12/17/2014)... Unidesk Corporation today announced that ... welcomed its inaugural class in August 2013, has ... support bring your own device (BYOD) and deliver ... The solution, comprised of Citrix XenDesktop ... and storage infrastructure and Unidesk virtual ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 No matter ... been able to eradicate the head louse parasite—a common ... for parents. Each year between six and twelve million ... the Miami-based lice removal treatment company comes to the ... and environmentally friendly. With its track record of customer ...
(Date:12/17/2014)... (HealthDay News) -- Expectant parents should leave prenatal picture-taking ... recommends. Use of ultrasound imaging and heartbeat monitors ... risk-free, the agency warns. "Although there is ... ultrasound imaging and heartbeat monitors, prudent use of these ... Vaezy, an FDA biomedical engineer, said in an agency ...
(Date:12/17/2014)... Kathleen Doheny HealthDay ... Chronic sleep loss is rampant in America, and work commitment ... is the No. 1 sleep killer," said Dr. Mathias Basner, ... the University of Pennsylvania Perelman School of Medicine. A ... older, found that work is the main activity exchanged for ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
Breaking Medicine News(10 mins):Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3
... HealthDay Reporter , TUESDAY, June 28 (HealthDay News) -- ... U.S. regulators, attention again Tuesday during a two-day hearing to ... the treatment of metastatic breast cancer. Back on Dec. ... of the drug to fight breast cancer, citing the ...
... University School of Medicine in St. Louis are performing ... irregular heartbeat. Available at only a handful of ... surgical techniques with the latest advances in catheter ablation, ... surface to block signals causing the heart to misfire. ...
... care nurses doubt that a clinical neurological examination can establish ... perceive that this uncertainty can affect relatives when the question ... from the Sahlgrenska Academy, University of Gothenburg, Sweden. ... caring for patients who are brain dead and who by ...
... with social interaction and attentiveness, and are also sensitive ... evident to parents during their child,s first two years, ... of Gothenburg. In her thesis, Dewrang investigated ... relative to their diagnosis. The thesis is based on ...
... mutations for two classes of p7 inhibitor, which may ... with current standard of care. Study results support the ... future HCV-specific therapies and are available in the July ... Wiley-Blackwell on behalf of the American Association for the ...
... regulated, as mistakes may lead to cancer. The so-called c-JUN ... and liver. The group of Veronika Sexl at the ... detail with the discovery an additional function of c-JUN,s also ... have recently been published in the open-access journal Oncotarget ...
Cached Medicine News:Health News:FDA to Hear Appeal on Breast Cancer Drug 2Health News:FDA to Hear Appeal on Breast Cancer Drug 3Health News:New procedure treats atrial fibrillation 2Health News:New procedure treats atrial fibrillation 3Health News:New procedure treats atrial fibrillation 4Health News:Intensive care nurses have doubts about method for establishing brain death 2Health News:Intensive care nurses have doubts about method for establishing brain death 3Health News:P7 protein resistance mutations identified; represent drug targets for hepatitis C virus 2Health News:The good, the bad and the ugly: The many roles of c-JUN in cancer 2
... operation for stent delivery. Uses perpendicular ... movement. Allows user to adjust stent ... Maintains tactile feel via fine adjustment ... in visualization at any angle. The ...
Vial with 100 Urine Reagent Test Strips, tests for glucose, protein, pH, blood, ketone, bilirubin, nitrite, urobilinogen, specific gravity. FOR LABORATORY USE BY QUALIFIED TECHNICIANS....
... the latest from Quality Mapping Solutions, ... designed specifically for implementing and managing ... superior design, functionality, security, and versatility ... managing a quality program., ,Based upon ...
... Q-Pulse is the UK's market-leading system ... 250 pathology laboratories in the UK ... In addition, hundreds of pathology laboratories ... South Africa and the United States ...
Medicine Products: